Clin2
NCT07514338Likely a fitNot yet recruiting

Long-term safety study of KL1333 for mitochondrial disease

Mitochondrial Diseases

Part of Hormones & metabolism clinical trials.

This is a follow-up study for patients who completed a previous trial (FALCON) testing KL1333, an experimental medicine for primary mitochondrial disease—a condition where cells don't produce enough energy. The study tracks how safe and effective the treatment remains over time.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
140 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have completed the earlier FALCON study and followed its rules closely
  • You are 18 years old or older
  • You can attend study visits on schedule and complete online questionnaires about how you feel
  • Your other medications will stay the same throughout the study (if possible)
  • You agree to stop taking idebenone (another mitochondrial disease medicine) during this study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06451757Recruiting· Phase 3
A trial of sonlicromanol for mitochondrial disease

This trial tests a new medicine, sonlicromanol, for people with a specific type of mitochondrial disease (caused by the m.3243A>G mutation) who also have chronic fatigue and muscle weakness. The goal is to see if it helps improve symptoms and daily function.

Boston, Massachusetts
NCT05569122Recruiting· Phase 1
Studying an MRI contrast method in mitochondrial muscle disease

This Phase 1 study tests a special MRI approach (using a contrast agent) to better measure changes in muscles in people with mitochondrial diseases. It also includes some healthy volunteers and other critically ill patients to compare results and check safety.

Philadelphia, Pennsylvania
NCT04802707Recruiting· Phase 2
Study drug for mitochondrial depletion disorder due to gene changes

This Phase 2 trial tests a treatment made from deoxynucleosides to help people with mitochondrial depletion disorder caused by certain gene changes. If you match the genetic diagnosis, the study may see whether the treatment improves symptoms or disease markers.

Montreal, Quebec
NCT05650229Recruiting· Phase 2
Study of KL1333 for adult mitochondrial disease fatigue and weakness

This Phase 2 trial studies whether KL1333 improves chronic fatigue and muscle weakness in adults with a confirmed mitochondrial genetic disease. You may be eligible if you have persistent fatigue for at least 3 months and signs of muscle involvement, and can safely follow study requirements.

Orange, California
NCT06890520Recruiting
Brain chemistry study for mitochondrial disease

This study looks at brain chemicals in people with primary mitochondrial disease using an MRI scan. It aims to understand how the disease affects the brain and may help guide future treatments.

Philadelphia, Pennsylvania
NCT05250375Recruiting
Study of mitochondrial muscle diseases over time

This natural history study follows children and adults with suspected or confirmed mitochondrial myopathy to better understand symptoms and how the condition changes. It may also include healthy participants to compare test results and improve future treatments.

Philadelphia, Pennsylvania

Hear when a new Mitochondrial Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.